Winners of the 1st Prize
at the NBG Business Seed Awards

Connecting the Dots in Biomedicine
with AI.

Accelerating and Optimizing the Roadmap to Effective Health Solutions for Patients and Physicians

REQUEST A MEETING
LPancreas a disruptive diagnostic solution for Diabetes

We have built an effective hybrid discovery approach, alternating in vitro with in silico steps. This allows us and our clients, the maximum exploitation of biologically/clinically relevant information. We deliver highly performing, mature and feasible solutions to be readily translated to bench top diagnostics and drive fast drug discovery. Our strength lies in bridging disciplines, in our highly specialised team, with years of research and development in biomarker and drug target discovery.
Join us as we develop a better future for healthcare.

Non-invasive Diagnostics

Minimally-invasive Diagnostics

Early Detection

Early Detection

Novel Drug Discovery

Novel Drug Target Discovery

Precision Medicine

Precision Medicine

Personalised Pharmacotherapy

Personalised Pharmacotherapy

Building a disruptive diagnostic method for diabetes

Prof. Ekaterini Alexiou-Chatzaki,
CEO & coFounder at ABCureD

Using AI/ML to Accelerate Innovation in Biomedicine

Biomarker and Drug Target Discovery

is Slow and Expensive

Most conditions are still poorly treated, with low therapeutic response rates. Whether it’s cancer, metabolic, neurodegenerative or immune diseases, there is a faster and less expensive way to reach better outcomes. ABCureD accelerates and optimizes the roadmap from research lab to clinic. We thrive on the momentum, transition from hypothesis-driven to big-data-driven development. Artificial Intelligence is changing the way we conduct R&D in biomedicine.

% = Non-respondents to treatment. Low therapeutic rate.

News

ABCureD at Voria.gr

ABCureD, a Greek spin-off, says its LPancreas is the world’s first blood test to assess pancreatic damage linked to diabetes

Read More »
May 19, 2026
Read All News
LPancreas logo
FROM INNOVATION to PRODUCT

Predict the onset of Diabetes

with a simple AI-powered diagnostic test that directly measures pancreatic decline
  • Blood-based analysis
  • Standard PCR lab technology
  • Diagnostic kit for 50 tests
  • Smart application
  • Score for diabetic progression
LPancreas Kit
Estimate Pancreatic Decline

Estimate Pancreatic Decline

  • Direct informed treatment choice
  • Support correct timely interventions
  • Identify high-risk individuals
  • Increase patient awareness
  • Prevent diabetic complications
  • Improve quality of life
  • Reduce healthcare costs
  • Improve treatment response fostering health & well-being
LEARN MORE
REQUEST A MEETING

Supporters

R&D, Consulting or Training

Need consulting, ideation, or AI-enabled analysis of biomedical data for validated laboratory solutions?
LET'S TALK

REQUEST A MEETING

Fill out the form below, and we will be in touch shortly.
Contact Information
Company Information
Preferred Date and Time Selection